Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)

• Company Description    Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. Number of Employees: 488

• Price / Volume Information    Yesterday's Closing Price: $27.56 Daily Weekly Monthly 20 Day Moving Average: 837,948 shares Shares Outstanding: 58.59 (millions) Market Capitalization: $1,614.80 (millions) Beta: 0.91 52 Week High: $46.00 52 Week Low: $22.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.44% 1.35% 12 Week -5.10% -6.04% Year To Date 1.25% 0.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 88 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-649-8600 fax: - ir@agios.com http://www.agios.com

• General Corporate Information    Officers Brian Goff - ChiefExecutiveOfficer Jacqualyn A. Fouse - Chair of the Board of Directors Cecilia Jones - Chief Financial Officer T.J. Washburn - Vice President; Controller Jay Backstrom - Director Peer Information Agios Pharmaceuticals, Inc. (CORR.) Agios Pharmaceuticals, Inc. (RSPI) Agios Pharmaceuticals, Inc. (CGXP) Agios Pharmaceuticals, Inc. (BGEN) Agios Pharmaceuticals, Inc. (GTBP) Agios Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00847X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/07/26 Share - Related Items Shares Outstanding: 58.59 Most Recent Split Date: (:1) Beta: 0.91 Market Capitalization: $1,614.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.80 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.63 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 29.08% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/07/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.35 Price/Cash Flow: - Price / Sales: 29.89 EPS Growth vs. Year Ago Period: -6.32% vs. Previous Quarter: -3.93% Sales Growth vs. Year Ago Period: 86.09% vs. Previous Quarter: 55.02% ROE 12/31/25 - -31.07 09/30/25 - -28.35 06/30/25 - -3.49 ROA 12/31/25 - -28.92 09/30/25 - -26.42 06/30/25 - -3.23 Current Ratio 12/31/25 - 11.46 09/30/25 - 13.82 06/30/25 - 14.48 Quick Ratio 12/31/25 - 11.06 09/30/25 - 13.39 06/30/25 - 14.04 Operating Margin 12/31/25 - -764.01 09/30/25 - -895.86 06/30/25 - -128.03 Net Margin 12/31/25 - -764.01 09/30/25 - -895.86 06/30/25 - 1,590.42 Pre-Tax Margin 12/31/25 - -765.89 09/30/25 - -915.68 06/30/25 - 1,698.66 Book Value 12/31/25 - 20.36 09/30/25 - 22.02 06/30/25 - 23.57 Inventory Turnover 12/31/25 - 0.20 09/30/25 - 0.19 06/30/25 - 0.17 Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©